Processing

Please wait...

Settings

Settings

Goto Application

1. EP1866643 - BIOMARKER FOR SENSITIVITY TO MTOR INHIBITOR THERAPY IN KIDNEY CANCER

Office European Patent Office
Application Number 06738793
Application Date 17.03.2006
Publication Number 1866643
Publication Date 19.12.2007
Publication Kind A2
IPC
G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
G01N 33/5091
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5091for testing the pathological state of an organism
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/178
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
178miRNA, siRNA or ncRNA
G01N 2333/4703
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4703Regulators; Modulating activity
G01N 2333/4704
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4703Regulators; Modulating activity
4704Inhibitors; Supressors
Applicants UNIV CALIFORNIA
Inventors SAWYERS CHARLES L
THOMAS GEORGE V
Designated States
Priority Data 2006009775 17.03.2006 US
66264905 17.03.2005 US
Title
(DE) BIOMARKER FÜR EMPFINDLICHKEIT GEGENÜBER MTOR-INHIBITORTHERAPIE BEI NIERENKREBS
(EN) BIOMARKER FOR SENSITIVITY TO MTOR INHIBITOR THERAPY IN KIDNEY CANCER
(FR) BIOMARQUEUR DESTINE AU TRAITEMENT DE LA SENSIBILITE A L'INHIBITEUR DU MTOR DANS LE CAS DU CANCER DU REIN
Abstract
(EN)
The invention disclosed herein provides methods for the examination and/ or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.

(FR)
La présente invention concerne un procédé destiné à l'examen et/ou la quantification des voies biochimiques qui sont régulées dans des pathologies telles que le cancer du rein. L'invention concerne également des réactifs et des nécessaires conçus pour la mise en oeuvre de ce procédé. Par exemple, on fait état d'une corrélation entre la perte du gène suppresseur de la tumeur VHL (Von Hippel-Lindau) et la sensibilité à l'inhibiteur du mTOR dans les cellules cancéreuses du rein humain, ce qui voudrait dire que cette perte confère à de telles cellules un avantage compétitif d'autonomie et d'angiogénicité.